(CLVT) CLARIVATE - Overview
Stock: Patent, Trademark, Research, Drug, Data
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 94.3% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.36 |
| Alpha | -79.61 |
| Character TTM | |
|---|---|
| Beta | 1.491 |
| Beta Downside | 1.420 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.87% |
| CAGR/Max DD | -0.51 |
Description: CLVT CLARIVATE January 12, 2026
Clarivate Plc (NYSE:CLVT) is a global information-services firm that segments its business into Academia & Government, Life Sciences & Healthcare, and Intellectual Property. It delivers research platforms such as ProQuest One, library-management suites (Alma, Polari, Vega), IP management tools (IPfolio, FoundationIP), patent-search software (Derwent Innovation), trademark services (CompuMark), and the Cortellis suite that supports drug-development decision-making. Its customer base spans universities, corporations, law firms, government agencies, and public libraries.
Key recent metrics: FY 2023 revenue reached roughly $1.73 billion, up about 8 % year-over-year, with subscription-based recurring revenue accounting for ~70 % of total sales. Operating margin held near 22 %, and free cash flow exceeded $300 million, underscoring strong cash generation. The life-sciences data segment is benefitting from a 4 % annual rise in global patent filings and accelerating R&D spend, while the broader research-services market is being amplified by AI-driven analytics and the push toward open-science initiatives.
For a deeper, data-driven assessment of CLVT’s valuation dynamics, you may find ValueRay’s analytical dashboards worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -396.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.55 > 1.0 |
| NWC/Revenue: -7.94% < 20% (prev -7.24%; Δ -0.70% < -1%) |
| CFO/TA 0.05 > 3% & CFO 609.9m > Net Income -396.0m |
| Net Debt (4.16b) to EBITDA (721.9m): 5.76 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (668.3m) vs 12m ago -7.01% < -2% |
| Gross Margin: 65.76% > 18% (prev 0.59%; Δ 6517 % > 0.5%) |
| Asset Turnover: 21.51% > 50% (prev 21.42%; Δ 0.08% > 0%) |
| Interest Coverage Ratio: -0.12 > 6 (EBITDA TTM 721.9m / Interest Expense TTM 269.3m) |
Altman Z'' -1.50
| A: -0.02 (Total Current Assets 1.29b - Total Current Liabilities 1.49b) / Total Assets 11.23b |
| B: -0.67 (Retained Earnings -7.52b / Total Assets 11.23b) |
| C: -0.00 (EBIT TTM -32.2m / Avg Total Assets 11.63b) |
| D: 0.78 (Book Value of Equity 4.90b / Total Liabilities 6.32b) |
| Altman-Z'' Score: -1.50 = D |
Beneish M -3.17
| DSRI: 1.08 (Receivables 810.7m/771.8m, Revenue 2.50b/2.58b) |
| GMI: 0.90 (GM 65.76% / 59.11%) |
| AQI: 1.00 (AQ_t 0.88 / AQ_t-1 0.88) |
| SGI: 0.97 (Revenue 2.50b / 2.58b) |
| TATA: -0.09 (NI -396.0m - CFO 609.9m) / TA 11.23b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of CLVT shares?
Over the past week, the price has changed by -18.49%, over one month by -36.28%, over three months by -36.84% and over the past year by -56.89%.
Is CLVT a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CLVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 113.4% |
| Analysts Target Price | 4.6 | 113.4% |
| ValueRay Target Price | 1.3 | -40.3% |
CLVT Fundamental Data Overview February 02, 2026
P/S = 0.7122
P/B = 0.3642
P/EG = 0.1712
Revenue TTM = 2.50b USD
EBIT TTM = -32.2m USD
EBITDA TTM = 721.9m USD
Long Term Debt = 4.42b USD (from longTermDebt, last quarter)
Short Term Debt = 37.4m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.16b USD (from netDebt column, last quarter)
Enterprise Value = 5.94b USD (1.78b + Debt 4.48b - CCE 318.7m)
Interest Coverage Ratio = -0.12 (Ebit TTM -32.2m / Interest Expense TTM 269.3m)
EV/FCF = 17.73x (Enterprise Value 5.94b / FCF TTM 335.2m)
FCF Yield = 5.64% (FCF TTM 335.2m / Enterprise Value 5.94b)
FCF Margin = 13.40% (FCF TTM 335.2m / Revenue TTM 2.50b)
Net Margin = -15.83% (Net Income TTM -396.0m / Revenue TTM 2.50b)
Gross Margin = 65.76% ((Revenue TTM 2.50b - Cost of Revenue TTM 856.5m) / Revenue TTM)
Gross Margin QoQ = 64.98% (prev 67.24%)
Tobins Q-Ratio = 0.53 (Enterprise Value 5.94b / Total Assets 11.23b)
Interest Expense / Debt = 1.53% (Interest Expense 68.5m / Debt 4.48b)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.4m (EBIT -32.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.87 (Total Current Assets 1.29b / Total Current Liabilities 1.49b)
Debt / Equity = 0.91 (Debt 4.48b / totalStockholderEquity, last quarter 4.90b)
Debt / EBITDA = 5.76 (Net Debt 4.16b / EBITDA 721.9m)
Debt / FCF = 12.41 (Net Debt 4.16b / FCF TTM 335.2m)
Total Stockholder Equity = 5.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.41% (Net Income -396.0m / Total Assets 11.23b)
RoE = -7.89% (Net Income TTM -396.0m / Total Stockholder Equity 5.02b)
RoCE = -0.34% (EBIT -32.2m / Capital Employed (Equity 5.02b + L.T.Debt 4.42b))
RoIC = -0.27% (negative operating profit) (NOPAT -25.4m / Invested Capital 9.51b)
WACC = 4.11% (E(1.78b)/V(6.26b) * Re(11.41%) + D(4.48b)/V(6.26b) * Rd(1.53%) * (1-Tc(0.21)))
Discount Rate = 11.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.25%
[DCF Debug] Terminal Value 85.71% ; FCFF base≈371.3m ; Y1≈349.5m ; Y5≈327.8m
Fair Price DCF = 8.60 (EV 9.85b - Net Debt 4.16b = Equity 5.69b / Shares 661.4m; r=5.90% [WACC]; 5y FCF grow -7.54% → 2.90% )
EPS Correlation: -59.57 | EPS CAGR: -22.61% | SUE: -1.59 | # QB: 0
Revenue Correlation: -12.45 | Revenue CAGR: 2.85% | SUE: 3.31 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=0.66 | Chg30d=-0.008 | Revisions Net=-3 | Growth EPS=+1.3% | Growth Revenue=-2.4%